Spyre Therapeutics, Inc.

SYRE

Spyre Therapeutics, Inc.

SYRE

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-25Shares Purchased (TTM):0Shares Sold (TTM):5,092,833

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:80,467,912Shares Outstanding:346,045Institutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Nonrelated Party	-	6	9	4	0	4	1	-	-	-	1	-
Related Party	-	6	9	4	0	4	1	11	-11	22	1	-
Preferred Stock Excluding Series A And B Non Votin…	-	0	0	0	0	0	0	-	-	-	0	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	162	97	86	65	82	48	89	72	45	228	189	91
Available For Sale Securities Debt Securities Curr…	983	644	671	421	445	516	514	343	381	257	150	113
Nontrade Receivables Current	-	-	-	-	-	-	-	-	-	-	0	0
Prepaid Expense And Other Assets Current	28	22	21	18	12	5	5	7	10	3	2	2
Assets Current	1,173	764	778	505	539	570	608	421	436	487	342	206
Other Assets Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Restricted Cash Noncurrent	-	-	0	-	-	-	0	0	0	0	0	1
Property Plant And Equipment Net	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Right Of Use Asset	-	-	-	-	-	-	-	-	-	-	0	0
Assets	1,173	764	778	505	539	570	608	421	436	488	342	207
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Trade Current	-	-	-	-	-	-	-	5	3	3	1	2
Derivative Liabilities Current	31	50	23	11	60	43	25	25	3	3	1	8
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Accrued Liabilities And Other Liabilities	26	29	27	24	19	22	28	13	6	22	13	16
Accounts Payable Other Current	-	-	-	-	-	-	-	-	-	16	17	20
Liabilities Current	63	85	59	46	83	71	54	58	22	43	32	45
Derivative Liabilities Noncurrent	7	7	4	3	0	16	37	36	40	39	41	21
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Other Liabilities Noncurrent	1	1	-	-	-	-	-	-	-	-	-	-
Liabilities	72	93	63	50	83	87	91	94	62	82	73	66
Preferred Stock Value	-	-	-	-	-	-	-	-	-	-	-	0
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	0	-	-	-	85	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,190	1,712	1,686	1,364	1,353	1,343	1,334	1,086	1,066	776	763	456
Accumulated Other Comprehensive Income Loss Net Of…	-2	-1	1	1	0	1	0	1	-1	-0	0	-0
Retained Earnings Accumulated Deficit	-1,233	-1,197	-1,128	-1,065	-1,054	-1,017	-972	-916	-847	-808	-764	-701
Stockholders Equity	1,101	671	715	455	456	483	518	327	374	152	184	-245
Liabilities And Stockholders Equity	1,173	764	778	505	539	570	608	421	436	488	342	207
Series A Non Voting Convertible Preferred Stock	-	0	0	0	-0	0	0	0	-0	0	0	0
Preferred Stock Excluding Series A Non Voting Conv…	-	-	-	-	-	-	-	0	0	0	0	-
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	0	-
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	-	0	-
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	-	0	-
Series B Non Voting Convertible Preferred Stock	-	0	0	0	-0	0	0	0	-0	0	0	-
Temporary Equity
Stockholders Equity Numbe…
Preferred Stock Par Or Stated Value Per Share	-	-	0	-	-	-	0	-	-	0	0	0
Preferred Stock Shares Authorized	-	-	10	-	-	-	10	-	-	9	10	9
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	0	-	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	0	-	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	0	-	-	-	0	-
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	20
Common Stock Shares Issued	88	79	78	60	60	60	60	51	51	37	36	4
Shares Outstanding	88	79	78	60	60	60	60	51	51	37	36	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.51%	23.77%	43.82%	-	-	-	-	-	-	-	-	-
2025	18.82%	18.35%	38.34%	-2.25%	-3.73%	38.53%	30.55%	43.34%	39.40%	5.50%	35.65%	98.48%
2024	-0.68%	-33.19%	-10.57%	17.11%	16.05%	41.79%	-24.57%	-37.20%	-42.69%	-1.09%	-31.03%	-17.37%
2023	-	-	-	16.00%	-2.00%	-14.72%	106.76%	127.24%	190.39%	50.15%	18.11%	37.76%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	18.53	8.97	13.25	10.90	6.49	8.06	11.26	7.32	19.70	11.38	10.68	4.59
Quick Ratio	18.09	8.71	12.89	10.51	6.34	7.99	11.16	7.20	19.26	11.32	10.61	4.54
Working Capital	1.11B	678.79M	719.10M	458.33M	455.77M	499.09M	554.41M	363.54M	413.61M	444.46M	309.55M	161.08M
Leverage & Debt
Debt to Equity	0.07	0.14	0.09	0.11	0.18	0.18	0.18	0.29	0.16	0.54	0.40	-0.27
Debt Ratio	0.06	0.12	0.08	0.10	0.15	0.15	0.15	0.22	0.14	0.17	0.21	0.32
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Per Share Metrics
Diluted EPS TTM	-	-518.53	-448.51	-430.49	-597.65	-603.78	-555.62	-621.02	-4.10	-9.98	-49.12	-68.57
Free Cash Flow Per Share TTM	-2.19	-536.43	-489.10	-349.32	-327.08	-490.87	-420.45	-437.07	-3.45	-3.04	-14.49	-20.26
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-39,428.92%	-27,347.97%	-20,450.76%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-52,939.68%	-38,238.15%	-27,934.72%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-40.94%	-61.96%	-81.84%
Net Income Growth (1Y)	-13.49%	-14.12%	-25.39%	-30.68%	11.20%	-42.64%	-38.60%	-27.01%	-31.76%	368.15%	304.21%	244.61%
EPS Growth (1Y)	-99.66%	-14.12%	-19.28%	-30.68%	14,462.40%	5,952.72%	1,031.13%	805.66%	-94.24%	-51.66%	97.58%	202.40%
Valuation Metrics
P/E TTM	-43.70	-0.10	-0.07	-0.04	-0.03	-0.03	-0.04	-0.05	-5.73	-3.80	-0.44	-0.18
P/B TTM	7.10	0.03	0.02	0.01	0.01	0.01	0.02	0.03	2.85	9.10	0.81	-0.21
P/S TTM	-	-	-	-	-	-	-	-	-	2,012.97	167.52	49.90
Market Cap	7.82B	17.45M	11.34M	5.80M	5.18M	5.58M	8.72M	10.18M	1.07B	1.38B	148.42M	52.60M
Enterprise Value	7.66B	-79.73M	-74.38M	-59.10M	-76.48M	-42.91M	-80.71M	-61.40M	1.02B	1.16B	-40.79M	-39.30M
Calculated Values
Free Cash Flow TTM	-192.57M	-185.63M	-169.25M	-120.88M	-113.18M	-169.86M	-157.41M	-151.25M	-156.42M	-110.82M	-99.91M	-87.01M
Net Debt	-162.01M	-97.19M	-85.72M	-64.90M	-81.66M	-48.49M	-89.42M	-71.58M	-45.47M	-227.87M	-189.22M	-91.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-25Sale

Owner: Burrows, Scott L

Title: Chief Financial Officer

Shares: 15,000

Price/Share: $87.13

Value: $1,306,950.00

Shares Owned: 97,994

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Fairmount, Funds Manageme…

Title: -

Shares: 4,684,781

Price/Share: $85.31

Value: $399,658,667.11

Shares Owned: -

Relationship: Director

Ownership: Indirect

2026-06-22Sale

Owner: Henderson, Michael Thomas

Title: -

Shares: 20,000

Price/Share: $100.00

Value: $2,000,000.00

Shares Owned: 68,606

Relationship: Director

Ownership: Direct

2026-06-03Sale

Owner: Sloan, Sheldon

Title: Chief Medical Officer

Shares: 8,333

Price/Share: $75.00

Value: $624,975.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Burrows, Scott L

Title: Chief Financial Officer

Shares: 7,500

Price/Share: $70.86

Value: $531,450.00

Shares Owned: 97,994

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-25	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	15,000	87.13	$1,306,950.00	97,994	4
2026-06-23	Fairmount, Funds Manageme…	Director	-	Indirect	Sale	4,684,781	85.31	$399,658,667.11	0	4
2026-06-22	Henderson, Michael Thomas	Director	-	Direct	Sale	20,000	100.00	$2,000,000.00	68,606	4
2026-06-03	Sloan, Sheldon	Officer	Chief Medical Officer	Direct	Sale	8,333	75.00	$624,975.00	0	4
2026-06-01	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	7,500	70.86	$531,450.00	97,994	4
2026-06-01	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	70.43	$1,056,450.00	597,540	4
2026-05-08	Henderson, Michael Thomas	Director	-	Direct	Sale	80,000	74.10	$5,928,000.00	88,606	4
2026-05-01	Sloan, Sheldon	Officer	Chief Medical Officer	Direct	Sale	78,333	72.62	$5,688,542.46	0	4
2026-05-01	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	12,500	71.37	$892,125.00	97,994	4
2026-05-01	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	72.40	$1,086,000.00	612,540	4
2026-04-01	Sloan, Sheldon	Officer	Chief Medical Officer	Direct	Sale	7,958	50.00	$397,900.00	0	4
2026-04-01	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	49.56	$743,400.00	627,540	4
2026-04-01	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	7,500	49.60	$372,000.00	97,994	4
2026-03-03	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	2,500	41.11	$102,775.00	97,994	4
2026-03-02	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	42.11	$631,650.00	642,540	4
2026-02-02	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	32.34	$485,100.00	657,540	4
2026-01-02	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	31.55	$473,250.00	671,907	4
2025-12-01	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	29.28	$439,200.00	686,907	4
2025-11-03	Turtle, Cameron	Director,Officer	Chief Executive Officer	Direct	Sale	45,000	23.40	$1,053,000.00	701,907	4
2025-09-02	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	18,428	16.26	$299,639.28	97,994	4
2024-11-06	Albers, Jeffrey W.	Director	-	Indirect	Sale	6,700	36.76	$246,292.00	27,360	4
2024-10-25	Albers, Jeffrey W.	Director	-	Indirect	Sale	300	36.43	$10,929.00	34,060	4
2024-09-03	Burrows, Scott L	Officer	Chief Financial Officer	Direct	Sale	18,531	28.17	$522,018.27	116,422	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

Inst. Shares: 80,467,912

Shares Outstanding: 346,045

2025-12-31

Inst. Shares: 77,855,929

Shares Outstanding: 346,045

2025-09-30

Inst. Shares: 63,632,589

Shares Outstanding: 346,045

2025-06-30

Inst. Shares: 62,347,507

Shares Outstanding: 346,045

2025-03-31

Inst. Shares: 61,567,003

Shares Outstanding: 346,045

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	80,467,912	346,045	-
2025-12-31	77,855,929	346,045	-
2025-09-30	63,632,589	346,045	-
2025-06-30	62,347,507	346,045	-
2025-03-31	61,567,003	346,045	-
2024-12-31	59,171,869	374,387	-
2024-09-30	50,755,969	346,045	-
2024-06-30	49,982,650	45,316,264	110.30%
2024-03-31	31,291,128	36,512,662	85.70%
2023-12-31	27,889,251	6,897,065	-
2023-09-30	2,922,972	4,293,812	68.07%
2023-06-30	68,699,485	3,822,605	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Spyre Therapeutics, Inc. (SYRE) — SEC Financial Statements & Analysis

Spyre Therapeutics, Inc. (SYRE) is a pharmaceutical preparations company, incorporated in DE. Spyre Therapeutics, Inc. trades on Nasdaq as: SYRE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Spyre Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 2012.97x (TTM), a Price-to-Book (P/B) ratio of 7.10x (TTM), at a market cap of $7.82B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.07x
P/S TTM: 2012.97x
P/B TTM: 7.10x
Market Cap: $7.82B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Spyre Therapeutics, Inc. in?

Spyre Therapeutics, Inc. (SYRE) operates in the Pharmaceutical Preparations industry.

What is SYRE's market cap?

Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $7.82B as of 2026-06-30.

What exchange does SYRE trade on?

Spyre Therapeutics, Inc. (SYRE) trades on the Nasdaq.

Where is Spyre Therapeutics, Inc. incorporated?

Spyre Therapeutics, Inc. is incorporated in DE.